Recombinant baculovirus and virus-like particle

• US 7,527,967 B2
• Filed: 11/24/2004
• Issued: 05/05/2009
• Est. Priority Date: 11/25/2003
• Status: Active Grant

• Current Assignee: Academia Sinica (Government of The Republic of China)
• Original Assignee: Academia Sinica (Government of The Republic of China)
• Inventors: Liu, Yen-Yen, Chao, Yu-Chan
• Primary Examiner(s): CHEN, STACY BROWN
• Application Number:
  US10/997,775
• Publication Number:
  US 20050208066A1
• Time in Patent Office: 1,623 Days
• Field of Search: None
• US Class Current: 435/320.1
• CPC Class Codes: A61K 2039/5256 expressing foreign proteins
• CPC Class Codes: A61K 2039/5258 Virus-like particles
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 15/1131 against viruses
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2310/14 interfering N.A.
• CPC Class Codes: C12N 2710/14123 Virus like particles [VLP]
• CPC Class Codes: C12N 2710/14143 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2760/16122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2760/16134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2770/20022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2770/20034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00
• CPC Class Codes: G01N 2333/11 Orthomyxoviridae, e.g. influenza virus
• CPC Class Codes: G01N 2333/165 Coronaviridae, e.g. avian infectious bronchitis virus
• CPC Class Codes: G01N 2500/02 Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
• CPC Class Codes: G01N 33/5005 involving human or animal cells immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025

Abstract

Recombinant baculoviruses, virus-like particles, and polypeptide that contain a protein sequence of a heterologous virus, related compositions, and related preparation, screening, delivery, detection, and treatment methods.

Claims

1. A recombinant baculovirus comprising a fusion heterologous polypeptide that contains a baculoviral envelope-targeting sequence, wherein the heterologous polypeptide is located on the surface of the baculovirus and the baculoviral envelope-targeting sequence consists of SEQ ID NO:

9.

2. The recombinant baculovirus of claim 1, wherein the heterologous polypeptide contains the sequence of a polypeptide of a heterologous virus.

3. The recombinant baculovirus of claim 2, wherein the heterologous virus is a coronavirus.

4. The recombinant baculovirus of claim 3, wherein the coronavirus virus is a severe acute respiratory syndrome coronavirus.

5. The recombinant baculovirus of claim 3, wherein the heterologous polypeptide contains the sequence of the envelope protein, membrane protein, nucleocapsid protein, or spike protein of the coronavirus, or an antigenic fragment thereof.

6. The recombinant baculovirus of claim 5, wherein the heterologous polypeptide contains one of SEQ ID NOs:

1-8, or an antigenic fragment thereof.

7. The recombinant baculovirus of claim 5, wherein the heterologous polypeptide contains the sequence of the spike protein of the coronavirus, or an antigenic fragment thereof.

8. The recombinant baculovirus of claim 7, wherein the heterologous polypeptide contains one of SEQ ID NOs:

5-8, or an antigenic fragment thereof.

9. The recombinant baculovirus of claim 2, wherein the heterologous peptide contains the extracellular domain sequence of hemagglutinin of an influenza virus.

10. The recombinant baculovirus of claim 9, wherein the heterologous polypeptide contains the extracellular domain sequence of hemagglutinin of an influenza A virus.

12. A method of identifying a compound for treating an infection with a virus, the method comprising:

incubating a first cell that binds to the virus and the recombinant baculovirus of claim 1 in a medium containing a compound; and

determining a level of the binding between the first cell and the recombinant baculovirus,

wherein the compound is determined to be effective in treating the infection if the level of the binding is lower than that determined in the same manner from a second cell except that the second cell is incubated in a medium free of the compound.

13. The recombinant baculovirus of claim 10, wherein the heterologous polypeptide contains SEQ ID NO:

10 or an antigenic fragment thereof.

11. The recombinant baculovirus comprising a fusion heterologous polypeptide that contains a baculoviral envelope-targeting sequence or a functional equivalent thereof, wherein the heterologous polypeptide is located on the surface of the baculovirus and the baculoviral envelope-targeting sequence contains SEQ ID NO:

9, and wherein the heterologous polypeptide contains SEQ ID NO;

10.